- Home
- COEP vs INKT Comparison
COEP vs INKT Comparison
Compare COEP & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- INKT
- Stock Information
- Founded
- COEP 2017
- INKT 2017
- Country
- COEP United States
- INKT United States
- Employees
- COEP N/A
- INKT N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- INKT Medicinal Chemicals and Botanical Products
- Sector
- COEP Health Care
- INKT Health Care
- Exchange
- COEP Nasdaq
- INKT Nasdaq
- Market Cap
- COEP 27.4M
- INKT 75.7M
- IPO Year
- COEP N/A
- INKT 2021
- Fundamental
- Price
- COEP $10.77
- INKT $17.30
- Analyst Decision
- COEP
- INKT Hold
- Analyst Count
- COEP 0
- INKT 3
- Target Price
- COEP N/A
- INKT $37.50
- AVG Volume (30 Days)
- COEP 56.9K
- INKT 2.9M
- Earning Date
- COEP 08-15-2025
- INKT 08-12-2025
- Dividend Yield
- COEP N/A
- INKT N/A
- EPS Growth
- COEP N/A
- INKT N/A
- EPS
- COEP N/A
- INKT N/A
- Revenue
- COEP $62,874.00
- INKT N/A
- Revenue This Year
- COEP N/A
- INKT N/A
- Revenue Next Year
- COEP N/A
- INKT N/A
- P/E Ratio
- COEP N/A
- INKT N/A
- Revenue Growth
- COEP N/A
- INKT N/A
- 52 Week Low
- COEP $2.31
- INKT $4.56
- 52 Week High
- COEP $13.70
- INKT $76.00
- Technical
- Relative Strength Index (RSI)
- COEP 59.53
- INKT 49.44
- Support Level
- COEP $11.30
- INKT $18.54
- Resistance Level
- COEP $12.71
- INKT $20.25
- Average True Range (ATR)
- COEP 0.89
- INKT 8.24
- MACD
- COEP 0.18
- INKT -1.13
- Stochastic Oscillator
- COEP 54.39
- INKT 13.41
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.